Researchers at Greater Manchester Mental Health NHS Foundation Trust and the Northern Care Alliance, working with colleagues in the Geoffrey Jefferson Brain Research Centre and international collaborators in Spain and Italy have found that people with both cognitive impairment and chronic kidney disease (CKD) had worse health outcomes than people with CKD alone.
The clinical investigation study was conducted at Salford Royal Hospital, part of Northern Care Alliance NHS Foundation Trust in Manchester, UK. The study was led by Chief Clinical Investigator Dr David Coope, a neurosurgeon at the Manchester Centre for Clinical Neuroscience and Brain Tumours Theme Lead at the Geoffrey Jefferson Brain Research Centre, and Chief Scientific Investigator Kostas Kostarelos, PhD, Professor of Nanomedicine at The University of Manchester, the Catalan Institute of Nanoscience & Nanotechnology, and Co-Founder of INBRAIN.
Our centre was proud to sponsor and attended an event in Manchester that bought together brain tumour experts from across the UK to discuss innovative ways to improve brain tumour diagnosis nationally.
The University of Manchester is the lead institute of a prestigious Alzheimer’s Society-funded Doctoral Training Centre award. A total of £2.9M has been awarded to fund the training and development of 29 PhD students over the next 8 years.
The NanoNeuroOmics project aims to bridge the gap between brain pathophysiology and molecular changes in the blood, focusing on two of the most challenging central nervous system disorders: Alzheimer’s disease (AD) and Glioblastoma (GBM).
An innovative bedside genetic test being implemented in Manchester could dramatically improve outcomes for thousands of people in the UK affected by stroke each year. The test can tell healthcare professionals in approximately one hour if stroke patients will be more likely to benefit from clopidogrel, the current first-line treatment to prevent recurrence.
An antibiotic with anti-inflammatory properties will be trialed in 45 stroke units across the UK starting in early 2025. The trial, led by Professor Craig Smith will determine whether this additional treatment will improve clinical and health economic outcomes.
Work on an imaging test to detect and monitor inflammation in brain tumours will take a step forward thanks to two new grants. Researchers within our brain imaging theme are developing a clinically applicable imaging test that could be used in all magnetic resonance imaging (MRI) scanners to help predict tumour growth and guide treatment.
Scientists from our brain tumour theme along with colleagues from the Manchester Centre for Clinical Neurosciences, part of Northern Care Alliance NHS Foundation Trust have published a paper in Neuro-Oncology Advances. It is the first in vivo evidence of increased TSPO expression and inflammation within the brains of patients with growing sporadic vestibular schwannomas.
Manchester is one of nine leading universities which will benefit from a record £35 million funding injection from the British Heart Foundation (BHF) to help strengthen world-leading cardiovascular disease research in the UK. The funding comes from the highly competitive Research Excellence Awards funding scheme.
Geoffrey Jefferson Brain Research Centre
Clinical Sciences Building
Northern Care Alliance
NHS Foundation Trust
Salford
M6 8FJ
Email: GJBRC@manchester.ac.uk
Recent Comments